Katherine A Sauder1,2,3, Jeanette M Stafford4, Shelley Ehrlich5, Jean M Lawrence6, Angela D Liese7, Santica Marcovina8, Amy K Mottl9, Catherine Pihoker10, Sharon Saydah11, Amy S Shah5, Ralph B D'Agostino4, Dana Dabelea. 1. Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado, Aurora, CO katherine.sauder@cuanschutz.edu. 2. Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. 3. Department of Epidemiology, Colorado School of Public Health, Aurora, CO. 4. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC. 5. Cincinnati Children's Hospital Medical Center and The University of Cincinnati, Cincinnati, OH. 6. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. 7. Department of Epidemiology and Biostatistics, University of South Carolina Arnold School of Public Health, Columbia, SC. 8. Northwest Lipid Research Laboratory, University of Washington, Seattle, WA. 9. Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, NC. 10. Department of Pediatrics, University of Washington, Seattle, WA. 11. Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
OBJECTIVE: To identify correlates of hemoglobin A1c (HbA1c) testing frequency and associations with HbA1c levels and microvascular complications in youth-onset diabetes. RESEARCH DESIGN AND METHODS: The SEARCH for Diabetes in Youth study collected data from individuals diagnosed with diabetes before age 20 at 8 years (n=1,885 type 1, n=230 type 2) and 13 years (n=649 type 1, n = 84 type 2) diabetes duration. We identified correlates of reporting ≥3 HbA1c tests/year using logistic regression. We examined associations of HbA1c testing with HbA1c levels and microvascular complications (retinopathy, neuropathy, or nephropathy) using sequentially adjusted linear and logistic regression. RESULTS: For type 1 diabetes, odds of reporting ≥3 HbA1c tests/year at 8 and 13 years diabetes duration decreased with older age at diagnosis (odds ratio [OR] 0.91 [95% CI 0.88-0.95]), longer duration of diabetes (OR 0.90 [0.82-0.99]), not having a personal doctor (OR 0.44 [0.30-0.65]), and lapses in health insurance (OR 0.51 [0.27-0.96]). HbA1c testing ≥3 times/year over time was associated with lower HbA1c levels (OR -0.36% [-0.65 to -0.06]) and lower odds of microvascular complications (OR 0.64 [0.43-0.97]) at 13 years duration, but associations were attenuated after adjustment for HbA1c testing correlates (OR -0.17 [-0.46 to 0.13] and 0.70 [0.46-1.07], respectively). For type 2 diabetes, not seeing an endocrinologist decreased the odds of reporting ≥3 HbA1c tests/year over time (OR 0.19 [0.06-0.63]), but HbA1c testing frequency was not associated with HbA1c levels or microvascular complications. CONCLUSIONS: We observed disparities in HbA1c testing frequency predominately by health care-related factors, which were associated with diabetes outcomes in type 1 diabetes.
OBJECTIVE: To identify correlates of hemoglobin A1c (HbA1c) testing frequency and associations with HbA1c levels and microvascular complications in youth-onset diabetes. RESEARCH DESIGN AND METHODS: The SEARCH for Diabetes in Youth study collected data from individuals diagnosed with diabetes before age 20 at 8 years (n=1,885 type 1, n=230 type 2) and 13 years (n=649 type 1, n = 84 type 2) diabetes duration. We identified correlates of reporting ≥3 HbA1c tests/year using logistic regression. We examined associations of HbA1c testing with HbA1c levels and microvascular complications (retinopathy, neuropathy, or nephropathy) using sequentially adjusted linear and logistic regression. RESULTS: For type 1 diabetes, odds of reporting ≥3 HbA1c tests/year at 8 and 13 years diabetes duration decreased with older age at diagnosis (odds ratio [OR] 0.91 [95% CI 0.88-0.95]), longer duration of diabetes (OR 0.90 [0.82-0.99]), not having a personal doctor (OR 0.44 [0.30-0.65]), and lapses in health insurance (OR 0.51 [0.27-0.96]). HbA1c testing ≥3 times/year over time was associated with lower HbA1c levels (OR -0.36% [-0.65 to -0.06]) and lower odds of microvascular complications (OR 0.64 [0.43-0.97]) at 13 years duration, but associations were attenuated after adjustment for HbA1c testing correlates (OR -0.17 [-0.46 to 0.13] and 0.70 [0.46-1.07], respectively). For type 2 diabetes, not seeing an endocrinologist decreased the odds of reporting ≥3 HbA1c tests/year over time (OR 0.19 [0.06-0.63]), but HbA1c testing frequency was not associated with HbA1c levels or microvascular complications. CONCLUSIONS: We observed disparities in HbA1c testing frequency predominately by health care-related factors, which were associated with diabetes outcomes in type 1 diabetes.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Giuseppina Imperatore; James P Boyle; Theodore J Thompson; Doug Case; Dana Dabelea; Richard F Hamman; Jean M Lawrence; Angela D Liese; Lenna L Liu; Elizabeth J Mayer-Davis; Beatriz L Rodriguez; Debra Standiford Journal: Diabetes Care Date: 2012-12 Impact factor: 19.112
Authors: Faisal S Malik; Jeanette M Stafford; Beth A Reboussin; Georgeanna J Klingensmith; Dana Dabelea; Jean M Lawrence; Elizabeth Mayer-Davis; Sharon Saydah; Sarah Corathers; Catherine Pihoker Journal: Pediatr Diabetes Date: 2019-12-16 Impact factor: 3.409